The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret

Neuropharmacology

Volumn 35, Issue 1, 1996, Pages 91-97

  Rudd, J A ^b   Bunce, K T ^c   Naylor, R J ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b The Chinese University of Hong Kong   (Hong Kong)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

antiemetic; dexamethasone; emesis; ondansetron

Indexed keywords

APOMORPHINE; CISPLATIN; COPPER SULFATE; DEXAMETHASONE; MORPHINE; ONDANSETRON; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; FERRET; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030027027     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/0028-3908(95)00137-9     Document Type: Article

References (34)

1. Allen D. A., Schertel E. R. and Bailey J. E. (1993) Reflex cardiovascular effects of continuous prostacyclin administration into an isolated in situ lung in the dog. J. Appl. Physiol. 74: 2928-2934.
2. 3 receptor antagonists as anti-emetics - preclinical evaluation and mechanism of action. Eur. J. Cancer 29A: S11-S16.
3. Andrews P. L. R. and Davis C. J. (1993) The mechanism of emesis induced by anti-cancer therapies. In: Emesis in Anti-cancer Therapy Mechanisms and Treatment (Andrews P. L. R. and Sanger G. S., Eds), pp. 113-161. Chapman & Hall Medical, London.
4. Andrews P. L. R., Davis C. J., Bingham S., Davidson H. I. M., Hawthorn J. and Maskell L. (1990) The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can. J. Physiol. Pharmac. 68: 325-345.
5. Andrews P. L. R., Rapeport W. G. and Sanger G. J. (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmac. Sci. 9: 334-341.
6. Barnes J. M., Barnes N. M., Costall B., Naylor R. J. and Tattersall F. D. (1988) Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology 27: 783-790.
7. Barnes N. M., Bunce K. T., Naylor R. J. and Rudd J. A. (1991) The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 30: 1073-1083.
8. Brenner W. E., Dingfelder J. R. and Stavrousky L. G. (1975) The efficacy and safety of intramuscularly administered 15(S)15 methylprostaglandin E2 methyl ester for induction of artificial abortion. Am. J. Obstet. Gynec. 123: 19-31.
9. Carpenter D. O., Briggs D. B., Knox A. P. and Strominger N. (1986) Radiation-induced emesis in the dog: effects of lesions and drugs. Radiat. Res. 108: 307-316.
10. Cersosimo R. J. and Karp D. D. (1986) Adrenal corticosteroids as anti-emetics during cancer chemotherapy. Pharmacotherapy 6: 118-127.
11. Costall B., Domeney A. M., Naylor R. J. and Tattersall, F. D. (1987) Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology 26: 1321-1326.
12. Costall B., Domeney A. M., Naylor R. J., Owera-Atepo J. B., Rudd J. A. and Tattersall F. D. (1990) Fluphenazine, ICS 205-930 and DL-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 29: 453-462.
13. Cubeddu L. X. and Hoffmann I. S. (1993) Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy -effects of anti-emetics. J. Clin. Pharmac. 33: 691-697.
14. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T. and Finn A. L. (1990) Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. New Engl. J. Med. 322: 810-816.
15. Curry S. L., Rine J., Whitney C. W., Nahhas W. A., Mortel R. and Demers L. M. (1981) The role of prostaglandins in the excessive nausea and vomiting after intravascular cisplatinum therapy. Gynecol. Oncol. 12: 89-91.
16. Eiler H. and Paddleforth R. (1979) Induction of intestinal evacuation or vomition (or both) in the dog by prostaglandin F2 alpha injection: clinical potential. Am. J. Vet. Res. 40: 1731-1733.
17. Ferreira S. H. (1972) Prostaglandins, aspirin-like drugs and analgesia. Nature 240: 200.
18. Flower R. J. (1974) Drugs which inhibit prostaglandin synthesis. Pharm. Rev. 26: 33-67.
19. Gandara D. R., Harvey W. H., Monaghan G. G., Perez E. A. and Hesketh P. J. (1993) Delayed emesis following high-dose cisplatin - a double-blind randomised comparative trial of ondansetron (GR-38032F) versus placebo. Eur. J. Cancer 29A: S35-S38.
20. 3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br. J. Cancer 61: 56-60.
21. Hawthorn J., Ostler K. J. and Andrews P. L. R. (1988) The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret. J. Exp. Physiol. 73: 7-21.
22. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br. J. Pharmac. 97: 247-255.
23. Hintze T. H., Kaley G. and Panzenbeck M. J. (1984) Mechanisms of reflex bradycardia and hypotension by metabolites of arachidonic acid in the cat. Br. J. Pharmac. 82: 117-125.
24. King G. L. (1990) Animal models in the study of vomiting. Can. J. Physiol. Pharmac. 68: 260-268.
25. Marr H. E., Davey P. D. and Blower P. (1992) The effect of dexamethasone, alone or in combination with granisetron, on cisplatin-induced emesis in the ferret. Br. J. Pharmac. 104: 317P.
26. Rath U., Upadhyaya B. K., Arechavala E., Bockmann H., Dearnaley D., Droz J. P., Fossa S. D., Henriksson R., Aulitzky W. E., Jones W. G., Weissbach L., Paska W. and Freeman A. (1993) Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 50: 168-172.
27. Roila F. (1993) Ondansetron plus dexamethasone compared to the standard metoclopramide combination. Oncology 50: 163-167.
28. Sanger G. S. (1993) The pharmacology of anti-emetic agents. In: Emesis in Anti-cancer Therapy Mechanisms and Treatment (Andrews P. L. R. and Sanger G. J., Eds), pp. 179-210. Chapman and Hall Medical, London.
29. Sanger G. S. and Andrews P. L. R. (1993) Afterword: unresolved issues and future prospects. In: Emesis in Anti-cancer Therapy Mechanisms and Treatment (Andrews P. L. R. and Sanger G. S., Eds), pp. 247-249. Chapman and Hall Medical, London.
30. Smith D. B., Newlands E. S., Spruyt O. W., Begent R. H. J., Rustin G. J. S., Mellor B. and Bagshawe K. D. (1990) Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br. J. Cancer 61: 323-324.
31. Stryker J. A., Demers L. M. and Mortel R. (1979) Prophylactic ibuprofen administration during pelvic cancer. Int. J. Radiat. Oncol. Biol. Phys. 5: 2049-2052.
32. Thompson P. I., Bingham S., Andrews P. L. R., Patel N., Joel S. P. and Slevin M. L. (1992) Morphine 6-glucuronide - A metabolite of morphine with greater emetic potency than morphine in the ferret. Br. J. Pharmac. 106: 3-8.
33. Vane J. R. (1974) Mode of action of aspirin and similar compounds. In: Prostaglandin synthetase inhibitors (Robinson H. J. and Vane J. R., Eds), pp. 155-173. Raven Press, New York.
34. Wilder-Smith O. H. G., Borgeat A., Chappuis P., Fathi M. and Forni M. (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72: 2239-2241.